GLABF (Gemina Laboratories) Return-on-Tangible-Equity: 0.00% (As of Oct. 2025)


What is Gemina Laboratories Return-on-Tangible-Equity?

Gemina Laboratories GLABF -27.59% Return-on-Tangible-Equity is 0.00% as of Oct. 2025. The stock has 2 warning signs investors should review.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gemina Laboratories's annualized net income for the quarter that ended in Oct. 2025 was $-0.96 Mil. Gemina Laboratories's average shareholder tangible equity for the quarter that ended in Oct. 2025 was $-3.59 Mil. Therefore, Gemina Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2025 was N/A%.

The historical rank and industry rank for Gemina Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

GLABF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.4
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Gemina Laboratories  (OTCPK:GLABF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Gemina Laboratories Return-on-Tangible-Equity Related Terms

Gemina Laboratories Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Return-on-Tangible-Equity Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Return-on-Tangible-Equity
0.00 -858.35 -1,283.86 0.00 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLABF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Gemina Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Return-on-Tangible-Equity falls into.


Gemina Laboratories Return-on-Tangible-Equity Calculation

Gemina Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jan. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jan. 2025 )  (A: Jan. 2024 )(A: Jan. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jan. 2025 )  (A: Jan. 2024 )(A: Jan. 2025 )
=-2.831/( (-1.181+-3.082 )/ 2 )
=-2.831/-2.1315
=N/A %

Gemina Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Oct. 2025 )  (Q: Jul. 2025 )(Q: Oct. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Oct. 2025 )  (Q: Jul. 2025 )(Q: Oct. 2025 )
=-0.956/( (-3.513+-3.676)/ 2 )
=-0.956/-3.5945
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Oct. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Gemina Laboratories (GLABF) has a Return-on-Tangible-Equity of 0.00% as of Oct. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Return-on-Tangible-Equity too high?
Gemina Laboratories' current Return-on-Tangible-Equity is 0.00%.
How does Gemina Laboratories' Return-on-Tangible-Equity compare to VRTX and REGN?
Gemina Laboratories' Return-on-Tangible-Equity of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Return-on-Tangible-Equity is 0.00% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.